Therapeutic plan model for induction protocol of non-promyelocytic acute myeloid leukemia
Keywords:Descritores: leucemia mielóide aguda, efeitos adversos, quimioterapia de indução, cuidados farmacêuticos.
Propose a treatment plan model for induction protocol of non- promyelocytic acute myeloid leukemia, focused on reducing the adverse events inherent to pharmacotherapy. An exploratory research using UpToDate® and Micromedex® databases of drug interactions, incompatibilities and adverse reactions related to the chemotherapeutic agents. The drugs analyzed were included in the induction protocol for acute myeloid leukemia and in the Pharmacotherapeutic Guide from a reference University Hospital in onco-hematology. The data were analyzed in detail from the technical point of view subsidizing the elaboration of a therapeutic plan model with the description of the principal cares and precautions associated with the use and ideal administration time for the drugs. 18 drug-drug interactions was identified and of these 83.3% (n = 15) have the potential for causing some adverse effect. As the outstanding incompatibilities, two have been identified, both physical and related to anthracycline daunorubicin. The most frequent adverse reactions was listed being myelosuppression with greater importance attached the use of cytarabine and followed by gastrointestinal effects. Already related to daunorubicin stands out with frequency greater than 10% such as abnormalities on electrocardiogram and alopecia. From the information obtained, was formulated a therapeutic plan model by means of a proposal with ideal administration time aiming to minimize the risks identified in the survey. The clinical pharmacist may signal through the proposed model care and precautions of conduct, increasing the team safety and promotes enhancing the quality of care provided to patients.
How to Cite
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.